View ValuationAccuStem Sciences 将来の成長Future 基準チェック /06現在、 AccuStem Sciencesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 01AccuStem Sciences, Inc. announced delayed annual 10-K filingOn 03/31/2026, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • May 16AccuStem Sciences, Inc. announced delayed 10-Q filingOn 05/15/2025, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01AccuStem Sciences, Inc. announced delayed annual 10-K filingOn 03/31/2025, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15AccuStem Sciences, Inc. announced delayed 10-Q filingOn 11/14/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15AccuStem Sciences, Inc. announced delayed 10-Q filingOn 08/14/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17AccuStem Sciences, Inc. announced delayed 10-Q filingOn 05/15/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 11Accustem Sciences Inc. Announces Resignation of Jeff Fensterer as Chief Operating Officer, Effective as of June 16, 2023On June 5, 2023, Jeff Fensterer, the Chief Operating Officer of AccuStem Sciences Inc. resigned his position with the Company for personal reasons, effective as of June 16, 2023. Jeff Fensterer will be moving to a consulting position with the Company.お知らせ • Nov 17Accustem Sciences Inc. Appoints Sean McDonald to Its Board of DirectorsAccuStem Sciences Inc. announced the appointment of Sean McDonald to its board of directors which will now comprise five members. Sean joins the company board while serving as the CEO of Ocugenix. Sean served as a director at Aethon from 2006 to 2017. From 2015 to 2016 Mr. McDonald was a venture partner with Adams Capital Management, a venture capital firm specializing in early-stage applied technology investments. Prior to that, from 2001 to 2014, Sean served as the CEO of Precision Therapeutics, one of the first biotechnology companies to marry breakthroughs in understanding of cancer biology and the use of machine learning with the goal of developing products that would help cancer patients get the most effective cancer treatment. From 2002 to 2008, Sean was also a director on the board of Respironics where he was a member of the audit and compensation committees leading up to its $5.1 billion acquisition by Phillips. Sean started his career in healthcare by founding Automated Healthcare which was one of the first companies to develop systems for automating the dispensing and administration of medication in hospital pharmacies. Mr. McDonald grew the organization from its inception to over 1,000 employees and oversaw the building of market access, clinical, product development and sales and marketing organizations. Automated Healthcare was ultimately acquired by McKesson Corporation where Sean became President of the automation group.お知らせ • Sep 15Accustem Sciences Inc., Annual General Meeting, Oct 10, 2022Accustem Sciences Inc., Annual General Meeting, Oct 10, 2022, at 09:00 Eastern Daylight. Location: the offices of Sheppard Mullin Richter & Hampton LLP located at 30 Rockefeller Plaza New York New York United States Agenda: To elect four members to board of directors; to ratify the appointment of Mazars USA LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022; to approve an amendment to Amended and Restated Certificate of Incorporation (the “Charter”), to effect a reverse stock split of outstanding shares of common stock by a ratio of any whole number between one-for-two and one-for-fifteen, at any time prior to October 10, 2023, the implementation and timing of which shall be subject to the discretion of our board of directors; and to transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.お知らせ • Apr 07Accustem Sciences Inc. announced that it expects to receive $2.67594 million in fundingAccustem Sciences Inc. announced a private placement of 1,337,970 common shares at the price of $2 per share for gross proceeds of $2,675,940 on April 5, 2022.お知らせ • Apr 06Accustem Sciences Inc. Appoints Wendy Blosser as Director to Serve on the BoardOn March 30, 2022, the Board of Directors of Accustem Sciences Inc. appointed Wendy Blosser, the company’s Chief Executive Officer as a director to serve on the Board and to hold office until the next annual meeting of stockholders and until her successor is duly elected and qualified, or until her prior death, resignation, retirement, disqualification or other removal.お知らせ • Mar 06+ 1 more updateAccuStem Sciences, Inc. Appoints New Executive Leadership TeamAccustem Sciences Inc. announced the formation of its executive leadership team as the first major step toward commercializing new products in the oncology space. Wendy Blosser, a commercial executive with extensive leadership experience at diagnostic companies in the oncology sector, has been named a member of the board of directors for AccuStem. Wendy most recently served as the Chief Commercial Officer for Agendia, a leading breast oncology company, where she led the organization to its highest sales volume and revenue since its inception. Prior to that, Wendy served as the Chief Commercial Officer at Biodesix where she oversaw the launch and rapid growth of its blood-based genomic testing, GeneStrat. Also joining the leadership team are Jeff Fensterer, as Chief Operations Officer, and Joe Flanagan, as Chief Business Officer. Jeff brings an exceptional track record in long term strategic planning that is enhanced by his experience in a broad spectrum of roles including marketing, sales, market access, lab operations and product development. Joe brings 25 years of sales excellence as a strategic expert in the commercial development and successful launch of new and on-market products. Both executives have led companies at various stages, from early start up to Fortune 500, to consistent and rapid growth in sales volume and revenue, most recently with Agendia. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、AccuStem Sciences は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:ACUT - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026N/A-2-1-1N/A12/31/2025N/A-2-1-1N/A9/30/2025N/A-2-1-1N/A6/30/2025N/A-200N/A3/31/2025N/A-1-1-1N/A12/31/2024N/A-2-1-1N/A9/30/2024N/A-1-1-1N/A6/30/2024N/A-2-1-1N/A3/31/2024N/A-2-1-1N/A12/31/2023N/A-2-2-2N/A9/30/2023N/A-3-2-2N/A6/30/2023N/A-3-2-2N/A3/31/2023N/A-4-3-3N/A12/31/2022N/A-4-2-2N/A9/30/2022N/A-3-1-1N/A3/31/2022N/A-100N/A12/31/2021N/A-1N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ACUTの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ACUTの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ACUTの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ACUTの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ACUTの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ACUTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 19:05終値2026/05/18 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋AccuStem Sciences, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 01AccuStem Sciences, Inc. announced delayed annual 10-K filingOn 03/31/2026, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • May 16AccuStem Sciences, Inc. announced delayed 10-Q filingOn 05/15/2025, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01AccuStem Sciences, Inc. announced delayed annual 10-K filingOn 03/31/2025, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15AccuStem Sciences, Inc. announced delayed 10-Q filingOn 11/14/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15AccuStem Sciences, Inc. announced delayed 10-Q filingOn 08/14/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17AccuStem Sciences, Inc. announced delayed 10-Q filingOn 05/15/2024, AccuStem Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 11Accustem Sciences Inc. Announces Resignation of Jeff Fensterer as Chief Operating Officer, Effective as of June 16, 2023On June 5, 2023, Jeff Fensterer, the Chief Operating Officer of AccuStem Sciences Inc. resigned his position with the Company for personal reasons, effective as of June 16, 2023. Jeff Fensterer will be moving to a consulting position with the Company.
お知らせ • Nov 17Accustem Sciences Inc. Appoints Sean McDonald to Its Board of DirectorsAccuStem Sciences Inc. announced the appointment of Sean McDonald to its board of directors which will now comprise five members. Sean joins the company board while serving as the CEO of Ocugenix. Sean served as a director at Aethon from 2006 to 2017. From 2015 to 2016 Mr. McDonald was a venture partner with Adams Capital Management, a venture capital firm specializing in early-stage applied technology investments. Prior to that, from 2001 to 2014, Sean served as the CEO of Precision Therapeutics, one of the first biotechnology companies to marry breakthroughs in understanding of cancer biology and the use of machine learning with the goal of developing products that would help cancer patients get the most effective cancer treatment. From 2002 to 2008, Sean was also a director on the board of Respironics where he was a member of the audit and compensation committees leading up to its $5.1 billion acquisition by Phillips. Sean started his career in healthcare by founding Automated Healthcare which was one of the first companies to develop systems for automating the dispensing and administration of medication in hospital pharmacies. Mr. McDonald grew the organization from its inception to over 1,000 employees and oversaw the building of market access, clinical, product development and sales and marketing organizations. Automated Healthcare was ultimately acquired by McKesson Corporation where Sean became President of the automation group.
お知らせ • Sep 15Accustem Sciences Inc., Annual General Meeting, Oct 10, 2022Accustem Sciences Inc., Annual General Meeting, Oct 10, 2022, at 09:00 Eastern Daylight. Location: the offices of Sheppard Mullin Richter & Hampton LLP located at 30 Rockefeller Plaza New York New York United States Agenda: To elect four members to board of directors; to ratify the appointment of Mazars USA LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022; to approve an amendment to Amended and Restated Certificate of Incorporation (the “Charter”), to effect a reverse stock split of outstanding shares of common stock by a ratio of any whole number between one-for-two and one-for-fifteen, at any time prior to October 10, 2023, the implementation and timing of which shall be subject to the discretion of our board of directors; and to transact such other matters as may properly come before the Annual Meeting and any adjournment or postponement thereof.
お知らせ • Apr 07Accustem Sciences Inc. announced that it expects to receive $2.67594 million in fundingAccustem Sciences Inc. announced a private placement of 1,337,970 common shares at the price of $2 per share for gross proceeds of $2,675,940 on April 5, 2022.
お知らせ • Apr 06Accustem Sciences Inc. Appoints Wendy Blosser as Director to Serve on the BoardOn March 30, 2022, the Board of Directors of Accustem Sciences Inc. appointed Wendy Blosser, the company’s Chief Executive Officer as a director to serve on the Board and to hold office until the next annual meeting of stockholders and until her successor is duly elected and qualified, or until her prior death, resignation, retirement, disqualification or other removal.
お知らせ • Mar 06+ 1 more updateAccuStem Sciences, Inc. Appoints New Executive Leadership TeamAccustem Sciences Inc. announced the formation of its executive leadership team as the first major step toward commercializing new products in the oncology space. Wendy Blosser, a commercial executive with extensive leadership experience at diagnostic companies in the oncology sector, has been named a member of the board of directors for AccuStem. Wendy most recently served as the Chief Commercial Officer for Agendia, a leading breast oncology company, where she led the organization to its highest sales volume and revenue since its inception. Prior to that, Wendy served as the Chief Commercial Officer at Biodesix where she oversaw the launch and rapid growth of its blood-based genomic testing, GeneStrat. Also joining the leadership team are Jeff Fensterer, as Chief Operations Officer, and Joe Flanagan, as Chief Business Officer. Jeff brings an exceptional track record in long term strategic planning that is enhanced by his experience in a broad spectrum of roles including marketing, sales, market access, lab operations and product development. Joe brings 25 years of sales excellence as a strategic expert in the commercial development and successful launch of new and on-market products. Both executives have led companies at various stages, from early start up to Fortune 500, to consistent and rapid growth in sales volume and revenue, most recently with Agendia.